These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

199 related items for PubMed ID: 17688972

  • 1. The role of alpha-adrenoreceptors in the treatment of urological diseases.
    Romics I.
    Neurochem Int; 2007 Oct; 51(5):328-31. PubMed ID: 17688972
    [Abstract] [Full Text] [Related]

  • 2. The role of combination medical therapy in benign prostatic hyperplasia.
    Greco KA, McVary KT.
    Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
    [Abstract] [Full Text] [Related]

  • 3. [Medical therapy of benign prostatic hyperplasia].
    Altarac S.
    Lijec Vjesn; 2005 Dec; 127(11-12):316-23. PubMed ID: 16583940
    [Abstract] [Full Text] [Related]

  • 4. [Drug therapy for benign prostatic syndrome (BPS)].
    Berges R.
    Aktuelle Urol; 2006 Sep; 37(5):351-62. PubMed ID: 17004180
    [Abstract] [Full Text] [Related]

  • 5. [The use of alpha-receptor blockers in urological diseases].
    Heimbach D, Frohmüller H.
    Dtsch Med Wochenschr; 1992 May 22; 117(21):825-8. PubMed ID: 1375139
    [No Abstract] [Full Text] [Related]

  • 6. Medical management of benign prostatic hypertrophy.
    Nix JW, Carson CC.
    Can J Urol; 2007 Dec 22; 14 Suppl 1():53-7. PubMed ID: 18163946
    [Abstract] [Full Text] [Related]

  • 7. Diagnosis and management of benign prostatic hyperplasia.
    Edwards JL.
    Am Fam Physician; 2008 May 15; 77(10):1403-10. PubMed ID: 18533373
    [Abstract] [Full Text] [Related]

  • 8. Pharmacology for common urologic diseases: 2011 review for the primary care physician.
    Liu XS, Folia C, Gomella LG.
    Can J Urol; 2011 Apr 15; 18 Suppl():24-38. PubMed ID: 21501548
    [Abstract] [Full Text] [Related]

  • 9. Adjunctive medical therapy with an alpha-1A-specific blocker after shock wave lithotripsy of lower ureteral stones.
    Wang CJ, Huang SW, Chang CH.
    Urol Int; 2009 Apr 15; 82(2):166-9. PubMed ID: 19322003
    [Abstract] [Full Text] [Related]

  • 10. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE.
    Roehrborn CG.
    BJU Int; 2008 Mar 15; 101 Suppl 3():17-21. PubMed ID: 18307681
    [Abstract] [Full Text] [Related]

  • 11. Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study.
    Yokoyama T, Uematsu K, Watanabe T, Sasaki K, Kumon H, Nagai A, Okayama Urological Research Group.
    Scand J Urol Nephrol; 2009 Mar 15; 43(4):307-14. PubMed ID: 19396723
    [Abstract] [Full Text] [Related]

  • 12. Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: who are the high-risk patients and what are the best treatment options?
    Robert G, Descazeaud A, de la Taille A.
    Curr Opin Urol; 2011 Jan 15; 21(1):42-8. PubMed ID: 21045706
    [Abstract] [Full Text] [Related]

  • 13. Impact of delaying 5-alpha reductase inhibitor therapy in men on alpha-blocker therapy to treat BPH: assessment of acute urinary retention and prostate-related surgery.
    Naslund M, Eaddy MT, Hogue SL, Kruep EJ, Shah MB.
    Curr Med Res Opin; 2009 Nov 15; 25(11):2663-9. PubMed ID: 19757985
    [Abstract] [Full Text] [Related]

  • 14. (Arylpiperazinyl)cyclohexylsufonamides: discovery of alpha(1a/1d)-selective adrenergic receptor antagonists for the treatment of Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms (BPH/LUTS).
    Chiu G, Li S, Connolly PJ, Pulito V, Liu J, Middleton SA.
    Bioorg Med Chem Lett; 2007 Jun 15; 17(12):3292-7. PubMed ID: 17452102
    [Abstract] [Full Text] [Related]

  • 15. Use of sympathetic alpha antagonists in the management of pediatric urologic disorders.
    Husmann DA.
    Curr Opin Urol; 2006 Jul 15; 16(4):277-82. PubMed ID: 16770128
    [Abstract] [Full Text] [Related]

  • 16. Contemporary patients with LUTS/BPH requiring prostatectomy have long-term history of treatment with alpha1-blockers and large prostates compared with past cases.
    Takeuchi M, Masumori N, Tsukamoto T.
    Urology; 2009 Sep 15; 74(3):606-9. PubMed ID: 19586655
    [Abstract] [Full Text] [Related]

  • 17. The long-term outcome of medical therapy for BPH.
    Madersbacher S, Marszalek M, Lackner J, Berger P, Schatzl G.
    Eur Urol; 2007 Jun 15; 51(6):1522-33. PubMed ID: 17416456
    [Abstract] [Full Text] [Related]

  • 18. Common approach to managing lower urinary tract symptoms and erectile dysfunction.
    Taylor JM, Desouza R, Wang R.
    Asian J Androl; 2008 Jan 15; 10(1):45-53. PubMed ID: 18087643
    [Abstract] [Full Text] [Related]

  • 19. Prostatic alpha adrenoceptors.
    Lepor H, Shapiro E.
    Prog Clin Biol Res; 1994 Jan 15; 386():271-7. PubMed ID: 7528394
    [No Abstract] [Full Text] [Related]

  • 20. [Current trends in the treatment of urological patients with transplanted kidney].
    Trapeznikova MF, Urenkov SB, Zubrilina NM, Podoĭnitsyn AA.
    Urologiia; 2009 Jan 15; (2):9-13. PubMed ID: 19526868
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.